An HIV/AIDS vaccine: where do we go from here?

Trends in Microbiology

Volumn 16, Issue 12, 2008, Pages 553-554

  Bernstein, Alan ^a  

^a Global HIV Vaccine Enterprise   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; DRUG RESEARCH; EDITORIAL; HEALTH CARE ORGANIZATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONAL COOPERATION; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; WORLD HEALTH;

EID: 56649111209     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2008.08.009     Document Type: Editorial

References (7)

1. Barré-Sinoussi F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
2. Gallo R.C., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224 (1984) 500-503
3. Klausner R.D., et al. The need for a global HIV/AIDS vaccine enterprise. Science 300 (2003) 2036-2039
4. Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. (2005) PLoS Med. 2, e25
5. Bernstein A. AIDS and the next 25 years. Science 320 (2008) 717
6. Shattock R.J., et al. Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med. 5 (2008) e81
7. Montefiori D., et al. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 4 (2007) e348